By Editorial TeamThere’s a lot of chatter out there about what big pharma does and doesn’t do for skin health, and most of it misses what companies like Bausch Health are actually doing to get treatments into patients’ hands.
Key Takeaways
- Bausch Health’s R&D budget is heavily pointed at common but tough conditions like psoriasis and acne, funding the development of new treatments.
- The company runs patient assistance programs that provide things like co-pay cards to cut out-of-pocket costs, making sure eligible people can actually afford their prescriptions.
- They don’t work in a bubble, Bausch Health builds partnerships with doctors’ offices and patient groups to spread good information and help people stick with their treatment plans.
- By finding efficiencies in how they manufacture drugs and manage their supply chain, they can better control costs, which helps keep prices from spiraling and ensures products are on pharmacy shelves.
- They’re constantly running clinical trials for chronic skin conditions, which is how the list of available therapies gets longer and gives hope to patients who’ve run out of options.
Myth 1: Pharmaceutical companies only focus on highly profitable, rare diseases.
It’s easy to think pharma giants only chase high-margin orphan drugs, but a look at Bausch Health’s portfolio shows a deep, ongoing investment in common skin problems. They have a huge footprint in treatments for acne, psoriasis, and rosacea, conditions that affect tens of millions of people, not a tiny few. When you consider the huge economic cost of these disorders (both in medical bills and lost workdays), it just wouldn’t make business sense to ignore them. For example, the American Academy of Dermatology (AAD) (https://www.aad.org/media/stats-common-skin-conditions) reported in 2023 that acne hits up to 50 million Americans every year, and psoriasis affects over 8 million. Bausch Health’s dermatology division plows money into R&D for new topicals and pills for exactly these people. You can see this in their pipeline, which is working on things like new retinoid and biologic formulations that make treatments work better with fewer side effects, which is what actually gets patients to stick with a therapy. They’ve already introduced advanced drugs that have been total game-changers for people with severe cystic acne or plaque psoriasis who had nowhere else to turn. This is about tackling a massive, persistent medical need.
The smoothest skin you've ever had, no razor required
Skip the daily shave. Find a top-rated waxing studio near you and book your first visit in minutes.
Find a Wax Studio Near You →Myth 2: Access to innovative skin solutions is primarily a matter of insurance coverage.
Insurance approval is just the first hurdle. The real challenge for many patients is the out-of-pocket cost. That’s why affordability and patient support programs are often the deciding factor in whether someone can get and stay on their medication. A lot of the newer, more effective dermatology treatments have high list prices. Even if your insurance covers it, you could be facing a massive deductible or co-pay that makes the drug impossible to afford. A patient with a $5,000 deductible whose medication costs $1,000 a month is in a tough spot. This is where patient assistance programs (PAPs) come in. Bausch Health and others run these programs to bridge that exact gap, offering co-pay assistance or even free medication to eligible people based on their income. Getting the drug is one thing, but using it correctly is another. That’s why real access also means providing educational materials or nurse hotlines, resources that help people manage side effects and understand their long-term treatment plan. It’s all part of making sure the prescription actually works.
Myth 3: Pharmaceutical companies don’t care about the real-world impact of their drug prices.
The idea that drug companies set prices in a vacuum and don’t care about affordability misses the business reality. A product isn’t viable if no one can access it. Bausch Health has to think about the financial burden, and they use a few levers to manage it. For one, look at their operations. They’re constantly trying to make manufacturing more efficient and tighten up the supply chain, because every dollar saved there gives them more pricing flexibility down the line. You also have to remember that dermatology is a competitive space. They can’t just slap any price on a product when there are other options, including generics or biosimilars for some advanced treatments. This pressure forces them to prove their drug’s value, whether through better results, a cleaner safety profile, or patient support services. Many also now enter into value-based contracts with insurance payers, where the price is tied to how well the drug actually works for patients. And a huge chunk of revenue goes right back into R&D. A 2024 PhRMA report (https://www.phrma.org/press-release/new-phrma-report-shows-biopharmaceutical-companies-are-focused-on-patient-access-and-affordability) confirms this reinvestment cycle: new, better drugs justify their development costs, assuming they are then made available to patients through all these different access programs.
Myth 4: Dermatological innovation has slowed down, with few new breakthroughs.
Anyone who thinks dermatology is stagnant hasn’t been paying attention. The last ten years, and especially the last five, have completely changed how we treat chronic inflammatory skin diseases. We’ve gone from relying on old-school topical steroids to having an entire arsenal of biologics and small molecule drugs that target the specific pathways causing the problem. This is the result of a much deeper understanding of skin biology, and it’s led to an explosion of dermatological innovation. Bausch Health is right in the middle of it, bringing new drugs to market and getting new uses approved for existing ones. These therapies have offered unheard-of levels of relief and have dramatically improved the quality of life for people with conditions like psoriasis and atopic dermatitis. Developing one of these drugs can take more than a decade and cost a fortune, so the commitment to running ongoing clinical trials to test new molecules and improve old ones is the exact opposite of a slowdown. And it’s not all about inventing brand new molecules. A lot of R&D goes into better delivery systems, making a topical cream less greasy or combining active ingredients so a patient only has to apply one product instead of two. That stuff matters for adherence.
Myth 5: Dermatological treatments are solely for cosmetic purposes and not serious health issues.
Calling most dermatology “cosmetic” is a dangerous oversimplification that minimizes serious medical conditions. Skin diseases can be physically and psychologically devastating, causing chronic pain, intense itching, and social isolation. Getting these treatments isn’t about vanity. It’s about managing conditions like severe psoriasis which, as the National Psoriasis Foundation (https://www.psoriasis.org/about-psoriasis/related-conditions/) points out, is linked to psoriatic arthritis, heart disease, and metabolic syndrome. Bausch Health’s drug portfolio clearly reflects this, with a major focus on therapies for skin cancer, chronic eczema, and severe infections. Access to these treatments is a medical necessity. It’s about stopping a disease from getting worse, easing real suffering, and improving a person’s overall health. For instance, treating certain precancerous skin spots can stop them from becoming deadly cancers. Controlling a chronic condition like eczema can prevent secondary infections and allow someone to work and have a normal social life. Writing off dermatological care as cosmetic ignores the science and the very real suffering of patients. When a company like Bausch Health focuses on both R&D and affordability programs, it makes a real difference in getting these necessary medical treatments to the people who need them.
What types of patient assistance programs does Bausch Health offer?
They have the standard co-pay cards that lower your out-of-pocket cost at the pharmacy, programs that provide free medication to uninsured or low-income patients who qualify, and resources to help your doctor’s office navigate the insurance paperwork. The whole point is to cut the financial hurdles for patients.
How does Bausch Health contribute to dermatological research?
Bausch Health pours a lot of money into its R&D pipeline to find new drug compounds and create better versions of existing treatments. They’re also constantly running large-scale clinical trials to prove that new therapies are safe and effective for a whole range of skin diseases before they come to market.
Are Bausch Health’s dermatological products only for severe conditions?
No, their portfolio is broad. It covers everything from very common problems like acne and rosacea that millions of people deal with, all the way to severe, chronic diseases like psoriasis, atopic dermatitis, and even some skin cancers. They try to offer something for the full range of skin health issues.
How does the company ensure availability of its skin solutions?
They manage this with a pretty sophisticated supply chain and efficient manufacturing. The goal is to have a tight distribution network that keeps pharmacies and clinics stocked, so that when a doctor writes a prescription, the patient isn’t told it’s on backorder. It’s about consistency.
Can patients directly apply for financial assistance for Bausch Health products?
Usually, no. While you can find program info on their website, the application process almost always has to go through your doctor. They need to sign off on it to confirm the prescription and your eligibility. The best first step is always to talk to your doctor’s office staff. They handle these forms all the time.
